Vumerity is an anti-multiple sclerosis drug owned by Biogen Inc. It contains the active ingredient diroximel fumarate. The drug entered the market on October 29, 2019, and is available in the form of delayed-release oral capsules.
The generics for Vumerity will likely be available after September 20, 2033. This expected date comes from the expiry of the last patent, titled 'Prodrugs of fumarates and their use in treating various diseases.'
Vumerity is primarily used for the treatment of multiple sclerosis. Its active ingredient, diroximel fumarate, works to manage the symptoms of this neurological condition and slow its progress.
Vumerity holds three patents; none of these have expired. The title 'Prodrugs of fumarates and their use in treating various diseases' is common to all, and they are set to expire on September 20, 2033. More information about these Vumerity generic-related patents is provided below: